AGX vs. KNSA
AGX (Argan, Inc.) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. AGX operates in Engineering & Construction (Industrials), while KNSA operates in Biotechnology (Healthcare). Over the past 5 years, AGX returned 77.59%/yr vs 29.69%/yr for KNSA. At a 0.16 correlation, their price movements are largely independent.
Performance
AGX vs. KNSA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AGX achieves a 136.30% return, which is significantly higher than KNSA's 33.60% return.
AGX
- 1D
- 2.69%
- 1M
- 12.57%
- YTD
- 136.30%
- 6M
- 127.40%
- 1Y
- 265.42%
- 3Y*
- 168.60%
- 5Y*
- 77.59%
- 10Y*
- 36.84%
KNSA
- 1D
- 1.66%
- 1M
- 3.51%
- YTD
- 33.60%
- 6M
- 27.60%
- 1Y
- 93.78%
- 3Y*
- 52.43%
- 5Y*
- 29.69%
- 10Y*
- —
AGX vs. KNSA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
AGX Argan, Inc. | 136.30% | 130.61% | 198.31% | 30.24% | -2.01% | -11.64% | 19.15% | 8.62% | -0.51% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 33.60% | 108.54% | 12.77% | 17.09% | 27.27% | -33.39% | 59.76% | -60.63% | 14.89% |
Correlation
The correlation between AGX and KNSA is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.16 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since May 24, 2018 | 0.16 |
Fundamentals
AGX:
$10.49B
KNSA:
$4.54B
AGX:
$11.38
KNSA:
$0.92
AGX:
64.90
KNSA:
59.85
AGX:
1.18
KNSA:
0.58
AGX:
10.05
KNSA:
5.80
AGX:
22.15
KNSA:
7.50
AGX:
$1.04B
KNSA:
$754.05M
AGX:
$217.93M
KNSA:
$294.06M
AGX:
$163.99M
KNSA:
$101.06M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AGX vs. KNSA — Risk / Return Rank
AGX
KNSA
AGX vs. KNSA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Argan, Inc. (AGX) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AGX | KNSA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.26 | ||
| Sortino ratioReturn per unit of downside risk | +0.48 | ||
| Omega ratioGain probability vs. loss probability | 1.48 | 1.41 | +0.07 |
| Calmar ratioReturn relative to maximum drawdown | 10.51 | 4.63 | +5.87 |
| Martin ratioReturn relative to average drawdown | 29.94 | 16.35 | +13.59 |
Loading charts...
Drawdowns
AGX vs. KNSA - Drawdown Comparison
The maximum AGX drawdown since its inception was -94.37%, which is greater than KNSA's maximum drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for AGX and KNSA.
Loading charts...
Drawdown Indicators
| AGX | KNSA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.37% | -83.06% | -11.31% |
Max Drawdown (1Y)Largest decline over 1 year | -24.96% | -21.12% | -3.84% |
Max Drawdown (3Y)Largest decline over 3 years | -43.75% | -34.14% | -9.61% |
Max Drawdown (5Y)Largest decline over 5 years | -43.75% | -53.17% | +9.42% |
Max Drawdown (10Y)Largest decline over 10 years | -54.61% | — | — |
Current DrawdownCurrent decline from peak | -0.28% | -7.35% | +7.07% |
Average DrawdownAverage peak-to-trough decline | -48.31% | -40.60% | -7.71% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.74% | 5.97% | +2.77% |
Volatility
AGX vs. KNSA - Volatility Comparison
Argan, Inc. (AGX) has a higher volatility of 17.73% compared to Kiniksa Pharmaceuticals, Ltd. (KNSA) at 10.40%. This indicates that AGX's price experiences larger fluctuations and is considered to be riskier than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AGX | KNSA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.73% | 10.40% | +7.33% |
Volatility (6M)Calculated over the trailing 6-month period | 54.86% | 34.02% | +20.84% |
Volatility (1Y)Calculated over the trailing 1-year period | 74.38% | 43.03% | +31.35% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 51.09% | 53.48% | -2.39% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 45.94% | 63.93% | -17.99% |
Dividends
AGX vs. KNSA - Dividend Comparison
AGX's dividend yield for the trailing twelve months is around 0.25%, while KNSA has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AGX Argan, Inc. | 0.25% | 0.52% | 0.93% | 2.24% | 2.71% | 1.94% | 7.31% | 2.49% | 1.98% | 4.44% | 1.42% | 2.16% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
AGX vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between Argan, Inc. and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AGX vs. KNSA - Profitability Comparison
AGX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Argan, Inc. reported a gross profit of 61.11M and revenue of 290.95M. Therefore, the gross margin over that period was 21.0%.
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.
AGX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Argan, Inc. reported an operating income of 45.40M and revenue of 290.95M, resulting in an operating margin of 15.6%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.
AGX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Argan, Inc. reported a net income of 46.06M and revenue of 290.95M, resulting in a net margin of 15.8%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.
Frequently Asked Questions
AGX and KNSA have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AGX has higher volatility (17.73%) compared to KNSA (10.40%). In terms of maximum drawdown, AGX dropped -94.37% vs KNSA's -83.06%.
AGX currently has the higher Sharpe Ratio (3.53 vs 2.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AGX and KNSA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer